{
    "clinical_study": {
        "@rank": "119318", 
        "acronym": "CAPTURE", 
        "arm_group": {
            "arm_group_label": "Treated with Ranibizumab in previous trial", 
            "description": "Treated with Ranibizumab in previous trial"
        }, 
        "brief_summary": {
            "textblock": "This research is being done to assess the long term prognosis of patients treated with\n      ranibizumab for edema due to retinal vein occlusion."
        }, 
        "brief_title": "Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "detailed_description": {
            "textblock": "People treated with ranibizumab for edema due to retinal vein occlusion as part of previous\n      studies at the Wilmer Eye Institute and who are currently being seen by their\n      ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients who have been enrolled in the following three trials will be included in\n             the study:\n\n        A)  \"A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple\n        Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein\n        Occlusions.\", B) \"Extended follow-up of patients with macular edema due to bRanch rETinal\n        vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with\n        intravitreal ranibizumab (RETAIN) \" C)  \"RanibizumabDosE Comparison (0.5mg and 2.0mg) and\n        the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach\n        (RELATE)\"\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients who have been enrolled in the following three trials will be included in the\n        study:\n\n        A)  \"A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple\n        Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein\n        Occlusions.\", B) \"Extended follow-up of patients with macular edema due to bRanch rETinal\n        vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with\n        intravitreal ranibizumab (RETAIN) \" C)  \"RanibizumabDosE Comparison (0.5mg and 2.0mg) and\n        the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach\n        (RELATE)\""
            }
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875770", 
            "org_study_id": "CAPTURE"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Retinal Vein Occlusion", 
        "lastchanged_date": "June 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "Wilmer Eye Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)", 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Peter Campochiaro, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean change from baseline in BCVA at 5 and 10 years.", 
            "measure": "Mean change from baseline in BCVA at 5 and 10 years.", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875770"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Peter A Campochiaro, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Mean change from baseline in foveal thickness at 5 and 10 years", 
            "measure": "Mean change from baseline in foveal thickness at 5 and 10 years", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}